ArticleAdvances in therapy2026

Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment.

Andrew J Cutler et al.PubMed ↗Publisher ↗

No numbers read from the abstract.